Provided by Tiger Fintech (Singapore) Pte. Ltd.

Beam Therapeutics, Inc.

24.12
-4.3600-15.31%
Volume:4.96M
Turnover:129.25M
Market Cap:1.96B
PE:-5.27
High:28.06
Open:28.03
Low:24.12
Close:28.48
Loading ...

Cantor Fitzgerald Upgrades Beam Therapeutics to Overweight From Neutral

MT Newswires Live
·
29 Jan

Wall Street Analysts Think Beam Therapeutics (BEAM) Could Surge 84.45%: Read This Before Placing a Bet

Zacks
·
28 Jan

Is it a Good Idea to Invest in Beam Therapeutics Stock Now?

Zacks
·
24 Jan

Positive Report for Beam Therapeutics (BEAM) from Bernstein

TIPRANKS
·
24 Jan

Has Alzamend Neuro (ALZN) Outpaced Other Medical Stocks This Year?

Zacks
·
23 Jan

Beam Therapeutics to encore data from BEACON Phase 1/2 trial of Beam-101

TIPRANKS
·
23 Jan

BRIEF-Beam Therapeutics To Encore Data From Beacon Phase 1/2 Clinical Trial Of Beam-101

Reuters
·
23 Jan

Beam Therapeutics to Encore Data From Beacon Phase 1/2 Clinical Trial of Beam-101 in Sickle Cell Disease at 2025 Tandem Meetings of Astct and Cibmtr

THOMSON REUTERS
·
23 Jan

Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR

GlobeNewswire
·
23 Jan

CRISPR Therapeutics Stock Falls 34% in a Year: Time to Buy or Sell?

Zacks
·
17 Jan

Bernstein Keeps Their Buy Rating on Beam Therapeutics (BEAM)

TIPRANKS
·
14 Jan

Is Beam Therapeutics (BEAM) Stock a Solid Choice Right Now?

Zacks
·
13 Jan

BRIEF-Beam Therapeutics Announces Progress In Hematology And Genetic Disease Franchises

Reuters
·
13 Jan

Beam Therapeutics Inc - Dosing to Commence in Beam-301 Trial in Early 2025

THOMSON REUTERS
·
13 Jan

Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts

THOMSON REUTERS
·
13 Jan

Beam Therapeutics Inc - Over 40 Adult Sickle Cell Patients Enrolled in Beacon Trial

THOMSON REUTERS
·
13 Jan